dr. amanj kamal f.i.c.m.s. cardiovascular surgery

33
Disorders of the arterial system Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Upload: bruno-davis

Post on 26-Dec-2015

222 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Disorders of the arterial system

Dr. Amanj KamalF.I.C.M.S. Cardiovascular Surgery

Page 2: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Turn the mobile offQuestions at the end

Page 3: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

AnatomyMain function of the arteries.Sizes; L, M, S. and ArteriolsWall composition according to sizes. (more

elastic in large ones)

Page 4: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Collaterals They are;Most organs got itSome not, (heart, kidney, retina). End

arteries.Eg. Subclavian arteryTime and chronicity

Page 5: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Physiology

Lamina

Page 6: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Intima as organ? 1%, surface area

Growth promotion and inhibition, Vasoconstriction and vasodilation, Blood cell adherence and nonadherence, Anticoagulation and procoagulation.

Smooth muscle cellsMajor bulkMechanical and structural supportProteoglycans.

Page 7: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Maintenance of vascular tone.Nitric oxide (NO), oxygen free radicals, endothelins,

angiotensinsCoagulation.Protien S, factor V, tissue factor, plasminogen

activators (and inhibitors)(PAs)(PAIs)Inflammatory and immunologic

response.The process of cell adherence, cell activation, and

cell migrationVascular wall modeling.platelet-derived growth factor (PDGF), and insulin-

like growth factor 1 (IGF-1).

Page 8: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Arterial Substitutes

Page 9: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

IntroductionLast 5o years of increased vascular surgery.In US: 350,000 synthetic, 200,000 autogenous

vein/yr.

Page 10: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

The optimal arterial substitute should be: Strong, inexpensive, and lasting for the life of the

patient; Easily and permanently attachable to the host

vessel; Biocompatible, and nonthrombogenic luminal

surface; Resist infection; Available in appropriate sizes; Remain patent without intervention; Have viscoelastic properties similar to those of a

normal artery.

Page 11: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

The optimal arterial substitute should not: Leak blood or serous fluid Degenerate chemically or physically with

time; Undergo abnormal proliferative responsePromote thrombus formation or be a source of

emboliOcclude when flexed.Damage blood components.

Page 12: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Arterial substitute evaluationPrimary patency,Secondary patency,Assisted primary patency, effectiveness of

follow up.

Page 13: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Allografts

Page 14: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Arterial allograftsWere the first widely used.Early results were encouraging.viability was not essential for successful

grafting.With ages (few yr.s loss of collagen, elastin …)Disappointing long term.High incidence of compoications. (abandond)

Page 15: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Saphenous Vein AllograftsHuman cadavers.Antigenic; immunologic rejection responseCryopreservation alone.Advances in immunosuppressionNo significant clinical application

Page 16: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Umbilical Vein AllograftsFrom human umbilical cords.Glutaraldehyde, ethanol, polyester mesh

tube.High pressure and nonantigenic.Patency rates of 70% and 50% at 1 and 5

years.Degenerative changes, aneurysms, difficult to

implant, No longer

Page 17: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Xenografts

Page 18: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Xenografts Unmodified arterial xenografts 1950sProminent immunologic reactionTreating bovine carotid arteriesModified xenografts 1960sPoor long-term patency rates, 40% 3 to 6

yearsaneurysms occurred in 3% to 6% infection rate of 3% to 7%Hemodialysis

Page 19: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Autografts

Page 20: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Arterial AutograftsAdvantages: no infection, flexible, no

aneurysm, blood supply, …Disadvantage: shortCABGRadial and internal mammaryPatency rate. And spasm.Internal iliac artery for renal.

Page 21: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Venous AutograftsMost successful and most clinically used.Saphenous vein, cephalic and brachial veins,

and superficial femoral and internal jugular veins

GSV; 70-80 cm, from to, valves, caliber…Types; Reverse, and In situ.patency of reversed 80-90% at 1 year, 55-

86% at 5 yearsreversed vein grafting is applicable to larger

numbers of patients,Occur; clamp stenosis, valve fibrosis, narrow

anast.

Page 22: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Prosthetic grafts

Page 23: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Textile GraftsConcept of :Mesh fabric would result in similar

healingWoven and knitted. Major differences Porosity Preclotting

Page 24: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Polytetrafluoroethylene (PTFE) GraftsFlexible All sizesFor extra anatomical bypass.

Page 25: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

So grafts’ types:Allografts:

- Artery- Saphenous vein- Umbelical vein

Xenografts: Autografts:

- Artery- Vein

Prosthetic grafts- Textile- PTFE

Page 26: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Complications of Prosthetic GraftingAnastomotic neointimal hyperplasia, Graft infection, Graft failure caused by fiber disruption or

stretching, Perigraft seromas, Anastomotic false aneurysms.

Page 27: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

PTFE

Page 28: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

PTFE

Page 29: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Dacron

Page 30: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Dacron

Page 31: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Dacron

Page 32: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Graft infection

Page 33: Dr. Amanj Kamal F.I.C.M.S. Cardiovascular Surgery

Any questions?